With these drugs, the fall in mean arterial pressure was preceded by a rise in the resistance index, which compensated for the initial fall in cardiac index. With each drug, the decrements in mean arterial pressure were associated with parallel decrements in the resistance index, and percent changes in mean arterial pressure and the resistance index were always significantly (p<O.OOl) correlated. At the end of the 24-hour period, the four drugs shared an equal antihypertensive effect, which varied 14-17%. This was associated with a return of the cardiac index toward control values by acebutolol, atenolol, and propranolol treatment and a moderately increased cardiac index above pretreatment values (13%, p<0.01) with pindolol. The secondary rise in the cardiac index was inversely correlated (p<0.001) with the fall in mean arterial pressure with all four drugs. Plasma renin was maximally suppressed 2 hours after treatment, thus before any change in mean arterial pressure had occurred with acebutolol, atenolol, and propranolol. Pretreatment values of active renin and the reduction of mean arterial pressure 24 hours after administration were not correlated in any of the four groups. Despite the "vasodilator" action of the four drugs, plasma norepinephrine did not rise. Our data show that the main hemodynamic change that occurs at the time blood pressure falls after jl-adrenoceptor antagonism is vasodilation. Neither autoregulation of blood flow nor renin suppression can explain this vasodilator action. The absence of an increase in norepinephrine, despite vasodilation, suggests that ,3-adrenoceptor antagonism interferes with sympathetic vasoconstrictor nerve activity. This effect may explain the vasodilator and antihypertensive potential of /3-adrenoceptor antagonists. (Circulation 1988;78:957-968) M ore than 20 years after the original observation by Prichard' that ,3-adrenoceptor antagonists lower blood pressure in hypertension, the mechanism of this action remains a
Several theories offer explanations for the effect of ,3-adrenoceptor antagonists on blood pressure, such as adjustment of the resistance vessels to reduced cardiac output through autoregulation of tissue perfusion,34 "resetting" of the arterial baroreflex,6 renin suppression,78 or attenuation of a-adrenoceptormediated vasoconstrictor nerve activity through a central action9'0 or through blockade of presynaptic ,B-adrenoceptors on postganglionic sympathetic nerve terminals." [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The introduction of p3-adrenoceptor antagonists with different so-called "ancillary" pharmacological properties has challenged some of these theories. For example, cardiac output and renin are suppressed to a lesser extent by ,3-adrenoceptor antagonists with a relatively high degree of partial agonist activity as compared with f-adrenoceptor antagonists lacking this property, yet the antihypertensive efficacy of these drugs is the same.2'4'15 Furthermore, for a central mode of action, the drug's penetration of the blood-brain barrier is a prerequisite. This occurs only to a minimal extent, if any, with highly hydrophilic ,B-adrenoceptor antagonists like atenolol, yet with these drugs, blood pressure reduction is no less than with lipophilic /8-adrenoceptor antagonists.2,12'f Thus, comparison of the hemodynamic and hormonal effects of,3-adrenoceptor antagonists with different ancillary properties may help to clarify their antihypertensive mechanism. In particular, the responses that occur at the time that blood pressure begins to fall may be informative.
In this study, we compared the effects of four orally administered ,3-adrenoceptor antagonists, each with different ancillary properties, for the first 24 hours after beginning treatment in 40 patients with uncomplicated essential hypertension. The following drugs were chosen: acebutolol, which is 8,1-selective with a moderate degree of partial agonist activity; atenolol, which is ,B1-selective, highly hydrophilic, and devoid of partial agonist activity; pindolol, which is nonselective with strong partial agonist activity; and propranolol, which is highly lipophilic, nonselective, and devoid of partial agonist activity. Because partial agonist activity is expressed most distinctly when sympathetic tone is low, all measurements were performed while patients were restricted to bed.
Patients and Methods Patients
Forty male patients with mild-to-moderate essential hypertension were studied. They were recruited from the outpatient hypertension clinic if their untreated sitting diastolic blood pressure was over 95 mm Hg on three separate occasions. The mean age of the patients was 45.5 years (range, 27-64 years). Routine clinical and laboratory investigations did not reveal causes of their hypertension. A history of or clinical signs of coronary or valvular heart disease, congestive heart failure, cerebrovascular disease, or chronic obstructive lung disease were all negative. After the purpose and the procedures of the study had been explained, all patients gave their consent to participate. The study protocol was approved by the local Hospital Ethical Review Committee.
Study Protocol
Antihypertensive and other types of medication, if any, were discontinued at least 3 weeks before the study. Blood pressure was measured in triplicate with a blind sphygmomanometer (London School of Hygiene Sphygmomanometer, Cinetronics, Middenhall, UK). 17 After this washout period, the patients were given placebos for 2 weeks. The placebo tablets were matched with the active medication with regard to appearance and number of tablets taken each day. After 1 week and after 2 weeks of placebo administration, all patients were hospitalized for 2 days. During both hospitalizations, the patients stayed in a single room and were restricted to bedrest. Catheterizations to perform hemodynamic measurements were started For determination of active plasma renin concentration, venous blood was collected in chilled tubes containing ethylenediaminetetraacetic acid in a final concentration of 2 mg/ml of blood. Samples were centrifuged immediately at 00 C and stored at -20°C until assay. Active plasma renin concentration was measured indirectly by a radioimmunoassay of angiotensin I as described previously.'9 For measurement of plasma catecholamines, 10 ml mixed venous blood was collected in chilled tubes containing 19 mg ethyleneglycol-bis-(/8-aminoethyl ether)-N,N,N',N'-tetraacetic acid and 12 mg gluthathione. After centrifugation at 00 C, samples were stored at -70°C until assay. Plasma norepinephrine and epinephrine were measured by a high-performance liquid chromatography system with electrochemical detection. 20 
Statistical Analysis
Data are presented as mean value + SEM. Because plasma values of active renin were not distributed normally, mean values were calculated after logarithmic transformation. The 24-hour blood pressure van Twenty-four hour trend plots of the hourly means of MAP and heart rate during placebo and after administration of acebutolol, atenolol, pindolol, or propranolol are shown in Figure 1 . Despite the fact that all patients were fully restricted to bed, a circadian rhythm of blood pressure and heart rate was maintained in all four groups. During placebo administration, heart rate increased after 2 AM by approximately 10 beats/min in all four groups. This increment in heart rate coincided with the second meal and with the somewhat less rigid circumstances of the protocol, although the patients remained in the recumbent position. Values of MAP and heart rate shortly before administration of the ,B-adrenoceptor antagonists did not differ from the corresponding values during placebo administration. After administration of acebutolol, atenolol, and propranolol, heart rate decreased within 1 hour compared with both placebo and baseline values, whereas no decrease in heart rate as compared with baseline occurred with pindolol. During the day, compared with placebo administration, heart rate was reduced by all four drugs. During the night, heart rate was reduced significantly only during acebutolol treatment, whereas it was increased, although not significantly, by pindolol. MAP was reduced (p<0.05) by 1 hour after pindolol adminis- tration. In contrast, the fall in MAP was delayed 2-3 hours during treatment with the other three drugs. Baseline values of MAP, heart rate, cardiac index, stroke index, and the systemic vascular resistance index in the four groups did not differ ( Table 2) . Administration of acebutolol, atenolol, and propranolol caused a rapid fall in the cardiac and stroke indexes (Figure 2 ). Two hours after drug treatment, the cardiac and stroke indexes were reduced, respectively, by 16+3% (p<0.01) and 10+2% (p<0.01) during acebutolol, 14+3% (p<0.001) and 7±2% (p<O.Ol) during atenolol, and 17 ± 3% (p<0.001) and 7 ± 3% (p<O.05) during propranolol treatment, whereas the cardiac and stroke indexes did not change after pindolol. Because MAP did not change initially, the decrements in cardiac index during acebutolol, atenolol, and propranolol treatment were associated with a proportional rise in the resistance index of 18 ±4% (p<0.01), 14 ±4% (p<0.001), and 18±4% (p<0.01), respectively. The rapid fall in MAP on pindolol was entirely due to a decrease in the resistance index. The more gradual decrease of MAP on acebutolol, atenolol, and propranolol was associated with a parallel decrease of the resistance index toward, and later even below, baseline values. During the gradual development of their full antihypertensive action, the cardiac and stroke indexes returned to control values, whereas these variables tended to increase above baseline on pindolol (Figure 2) . At the end of the 24-hour period, MAP was decreased to the same degree by the four drugs (Table 2 and Figure 2) . At this time, MAP and the resistance index were reduced, respectively, by 18 ± 3% (p<0.001) and 16 ± 6% (p<0.01) with acebutolol, 14±2% (p<0.01) and 11±4% (p<0.05) with atenolol, 15±2% (p<0.001) and 25±+-4% (p<0.001) with pindolol, and 15±4% (p<0.01) and 15 + 5% (p<0.01) with propranolol. At the end of the 24-hour period, the cardiac index was moderately increased during pindolol treatment (13±6%, p<0.01), whereas the cardiac index was not different from control values on the other three drugs ( Table 2) .
Hemodynamic Interrelations
With all four drugs, there were strong positive correlations between the percent changes of MAP and the resistance index, whereas the percent changes between MAP and the cardiac index were inversely correlated ( Figure 3 and Table 3 ). The regression lines as defined by the equations listed in Table 3 are depicted in Figure 4 . The slopes of the lines (MAP vs. the cardiac index or MAP vs. the resistance index) did not differ between the four groups. The rise in the cardiac index (toward baseline on acebutolol, atenolol, and propranolol and above baseline on pindolol) that accompanied the "vasodilator' action of the four drugs was due to an increase in both heart rate and the stroke index. Significant inverse correlations between the percent changes of the resistance index and the percent changes in either heart rate or stroke index were present with all four drugs ( Figure 5 and Table 4 Table 3 .
resistance index between the four groups did not differ ( Figure 6 and 
Discussion

Hemodynamic Effects
The hemodynamic responses to the four j3-adrenoceptor blocking agents in the first hours after the initial oral doses largely agree with previously reported hemodynamic responses to these drugs when administered intravenously.2,21,22 A rapid fall in cardiac output, heart rate, and stroke volume was observed after administration of acebutolol, atenolol, and propranolol, whereas no initial changes in these variables occurred with pindolol. Earlier studies with intravenous doses of acebutolol have shown that the magnitude of the fall in cardiac output of this drug is intermediate between that of pindolol and propranolol. 2, 2122 In the present study, the cardiodepressant effect of acebutolol was approximately the same as that of atenolol and propranolol. The somewhat higher baseline values of heart rate and cardiac output in the acebutolol group compared with the other three groups may partly explain the present findings.
The fall in cardiac output after administration of acebutolol, atenolol, and propranolol was associated with a rise in systemic vascular resistance. This vasoconstrictor response was proportional to the fall in cardiac output, both with the nonselective ,B-adrenoceptor antagonist propranolol as with A latency of several hours after starting treatment and the fall in blood pressure is a well-known, yet unexplained, feature of ,3-adrenoceptor antagonists. A similar latency was also observed in this study with acebutolol, atenolol, and propranolol. With pindolol, however, blood pressure was significantly reduced by 1 hour after administration, which confirms an early study by Anavekar et al. 25 Absence of cardiodepression and reflex vasoconstriction is a major contrast between pindolol and the other three drugs. It could be argued therefore, that the initial vasoconstrictor response per se accounts for the delayed onset of the blood pressure-lowering effect of,3-adrenoceptor antagonists devoid of a significant degree of partial agonist activity. Experiments in the spontaneously hypertensive rat support this view. 26 With all four drugs, the onset of the blood pressure-lowering effect coincided with a gradual decline in systemic vascular resistance. The identical slopes of the regression lines depicting the relation between the fall in blood pressure and the fall in vascular resistance in the four groups (Figure 4) show that the mechanism behind this relation is independent of ancillary properties such as 813-selectivity or partial agonist activity.
The long-term antihypertensive response to /3-adrenoceptor antagonists lacking partial agonist activity has been reported to be invariably associated with a reduction in cardiac output.2 The current data are at variance with these reports. The onset of blood pressure reduction after administration of acebutolol, atenolol, and propranolol was associated with a return of the initially reduced cardiac output, stroke volume, and heart rate to baseline values. Moreover, with pindolol treatment, cardiac output, stroke volume, and heart rate even rose above baseline. With all four drugs, the magnitude of these changes in cardiac output was inversely correlated with the magnitude of the fall in blood pressure, suggesting that this phenomenon reflects an adjustment to the "vasodilator" action of these drugs. Restoration of an initially depressed cardiac function at the onset of their hypotensive action has also been noted in other studies34 with atenolol and the nonselective /3-adrenoceptor antagonist timolol.3,4 Because this increment in cardiac output occurs despite blockade of,-adrenoceptors, withdrawal of vagal tone, an increase in venous return to the heart, and reduction of afterload rather than sympathetic stimulation are the factors most likely to be involved in this hemodynamic adaptation. This contention is supported by a previous study that showed that withdrawal of vagal tone contributes considerably to the increments in heart In the present study, the vasodilator action of the four drugs was not associated with a decrease in plasma norepinephrine; one should emphasize, how- ever, that the vasodilator action was not associated with an increase in plasma norepinephrine either. This contrasts with the effects of direct-acting vasodilators like hydralizine, minoxidil, and sodium nitroprusside. Vasodilatation during administration of these drugs is associated with a marked increase in plasma norepinephrine, reflecting baroreflex-mediated activation of the sympathetic nervous system. [41] [42] [43] In this regard, the absence of a rise in plasma norepinephrine during the vasodilator action of 8-adrenoceptor antagonists can be considered inappropriate and could therefore suggest interference of these drugs with the sympathetic nervous system.
Conclusions
The data from this study clearly show that the most important hemodynamic change during the onset of the hypotensive action of fi-adrenoceptor antagonists is vasodilatation. Our data do not support an important role for autoregulation of blood flow or renin suppression in the vasodilator action of,-adrenoceptor antagonists. Indirect evidence suggests that ,B-adrenoceptor antagonists have the ability to interfere with the activity of the sympathetic nervous system. Reduced vasoconstrictor nerve activity through blockade of central ,Badrenoceptors or through blockade of presynaptic ,B-adrenoceptors could be an explanation for our findings. The lack of a substantial difference between the hemodynamic responses to highly lipophilic propranolol and highly hydrophilic atenolol seems to favor the latter possibility.
During moderately elevated levels of sympathetic tone, the apparent vasodilator effect of /3-adrenoceptor antagonists is masked. In this situation, the sympathetic tone to the heart is high, and 3-adrenoceptor antagonism will result in a relatively greater reduction in cardiac output than in blood pressure. On the basis of the data obtained under strict basal conditions, we also believe that vasodilatation, that is, a fall in vascular resistance from a higher to a lower level, underlies the antihypertensive effect of 3-adrenoceptor antagonists. This view is supported by the fact that the fall in vascular resistance with the increasing levels of physical exercise is enhanced during /-adrenoceptor blockade.
Thus, ,3-adrenoceptor antagonists may or may not increase systemic vascular resistance in hypertension, depending on a number of factors: 1) the duration of ,-adrenoceptor blockade, 2) the magnitude of the antihypertensive response, 3) their degree of partial agonist activity, and 4) the level of (cardiac) sympathetic drive. Under all circumstances, however, it is the ability of these drugs to interfere with sympathetic vasoconstrictor nerve activity that is likely to be responsible for their blood pressurelowering efficacy.
